drugset
drugset / Trial / NCT04577534

COVID-19: Salvage TOcilizumab as a Rescue Measure

NCT04577534 ↗

Phase 3 Completed 88 enrolled Turku University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluating the efficacy of Tocilizumab in hospitalized patients in the inflammatory phase of COVID-19. Randomization 2:1 (TCZ:standard of care).

Timeline

Start
2020-08-14
Primary completion
2021-06-16
Completion
2021-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocillizumab Unknown — Intravenous

Indications

COVID-19